Corporate objectives
FibroStatin SL is engaged with the research and development of novel diagnostic and therapeutic products for human disorders in which GPBP proteins are useful as diagnostic biomarkers or therapeutic targets. These disorders include immune-complex-mediated glomerulonephritis and cancer, where the increased expression of GPBP has been shown to have a relevant role.
All the projects of FibroStatin SL are based on proprietary technology whose industrial rights have been protected through issued or pending international patents.
